A single tablet combination of linagliptin and metformin has been launched.
The combination therapy is available in two doses (2.5mg/850mg and 2.5mg/1000mg), which should be taken twice-daily for the treatment of adults with type 2 diabetes.
It is being marketed under the brand name Jentadueto by Boehringer Ingelheim and Eli Lilly.
They described the product as an “alternative oral regimen, which aims to improve glucose control whilst minimising the pill burden”.
Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.
Alternatively it is indicated in combination with a sulphonylurea in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
Phases III trial results suggested the combination led to slightly better reduction in HbA1C than the two constituents given as monotherapy.
Gwen Hall, diabetes specialist nurse in primary care for NHS Surrey, said: “My patients regularly raise concerns around remembering to take their various treatments at different times of the day.
“Jentadueto may provide a practical treatment option for people with type 2 diabetes by reducing the number of medicines they take each day for their diabetes.”